Description: Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Home Page: www.collegiumpharma.com
100 Technology Center Drive
Stoughton,
MA
02072
United States
Phone:
781 713 3699
Officers
| Name | Title |
|---|---|
| Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder & Chairman |
| Ms. Colleen Tupper | Executive VP & CFO |
| Ms. Shirley R. Kuhlmann J.D. | Executive VP, General Counsel, Chief Administrative Officer & Secretary |
| Mr. Scott Dreyer | Executive VP & Chief Commercial Officer |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive VP & Chief Medical Officer |
| Mr. Vikram Karnani | CEO, President & Director |
| Dr. Christopher Shayne James M.D. | Vice President of Investor Relations |
| Mr. Bart J. Dunn | Executive Vice President of Strategy & Corporate Development |
| Mr. Scott Sudduth | Head of Technical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 4.6751 |
|---|---|
| Trailing PE: | 12.6697 |
| Price-to-Book MRQ: | 4.08 |
| Price-to-Sales TTM: | 1.5292 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 197 |